Advertisement

Updated Analysis of the CANDOR Trial: Carfilzomib, Dexamethasone, and Daratumumab (KdD) vs Carfilzomib/Dexamethasone (Kd) in Relapsed or Refractory Multiple Myeloma
Posted: 12/16/2021 | By: Matthew Stenger

Question 1 of 5

The progression-free survival hazard ratio for KdD vs Kd in the updated analysis was:

Choose 1

A
HR = 0.63, P = .0027
B
HR = 0.60, 95% CI = 0.44–0.81
C
HR = 0.55, 95% CI = 0.39–0.78
D
HR = 0.59, P < .0001

CategoriesView All Quizzes

Tumor Type


Additional Topics



Conference Coverage